News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research> JPM Raises INNOVENT BIO (01801.HK) TP to HKD113; 1Q Product Sales Far Exceed Expectations
JPM released a research report stating that INNOVENT BIO (01801.HK) recorded 1Q product sales revenue of over RMB3.8 billion, representing a YoY increase of more than 50%, signific...
Reset
Send
The window will close in 5 seconds
<Research> JPM Raises INNOVENT BIO (01801.HK) TP to HKD113; 1Q Product Sales Far Exceed Expectations
Close
Recommend
4
Positive
4
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

JPM released a research report stating that INNOVENT BIO (01801.HK)  +2.450 (+2.722%)    Short selling $299.65M; Ratio 27.401%   recorded 1Q product sales revenue of over RMB3.8 billion, representing a YoY increase of more than 50%, significantly exceeding the banks and the markets expectations. The strong performance was mainly driven by several key products, including Mazdutide, Tolebrutinib and IBI-351. The bank estimated that Mazdutide sales increased by RMB100 million to RMB200 million QoQ.

In view of the robust growth momentum in 1Q, JPM raised its 2026 product revenue forecast for INNOVENT BIO by 6% to RMB16.1 billion, and lifted its 2027 and 2028 forecasts by 2% to 3% to RMB19 billion and RMB21 billion, respectively. The 2026 EPS forecast was also increased by 11.3%.

Related News BofAS: Innovent Biologics (01801.HK) Feb Sales YoY +32%, Rating Buy
JPM maintained an Overweight rating on INNOVENT BIO, raising its TP from HKD111 to HKD113, based on a discounted cash flow valuation with a weighted average cost of capital of 10.6% and a terminal growth rate of 3%. The bank continues to regard INNOVENT BIO as one of its top picks in Chinas biotechnology sector. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-04 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.